跳至主要内容
临床试验/NL-OMON29786
NL-OMON29786招募中不适用

ifeLines: the pilot study - LifeLines

niversitair Medisch Centrum Groningen0 个研究点目标入组 2,000 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
2,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Patients registered in a general practice in Sneek, The Netherlands, between 25 and 50 years of age.

排除标准

  • Severe psychiatric or physical illness, which makes participation in a broad study unfavourable, e.g. a terminal illness.
  • Not being able to understand the Dutch language.

研究者

相似试验

招募中
不适用
The ‘Link onto Life’ Program: A Pilot Intervention using Dialectical Behaviour Therapy (DBT) to Enhance Coping and Wellbeing in Young People (18-24 years).
ACTRN12615000943549Dr Suzanne Dziurawiec48
已完成
不适用
Pilot study on the feasibility and efficacy of individual psychooncological intervention to better cope with therapy-related stress in oncological patients under radiotherapy (With internal strength through radiation therapy)Head/neck tumoursC32Malignant neoplasm of larynx
DRKS00013493niversitätsklinikum HeidelbergAbteilung Innere Medizin und Psychosomatik15
已完成
不适用
Evaluation of Eclipse - A support group for people who have attempted suicideAttempted suicideMental Health - Suicide
ACTRN12619000542190niversity of New England130
进行中(未招募)
不适用
Pilot Study to define the Feasibility of Cytokine Release for Testing Efficacy of the Additon of Alanyl-Glutamine-Dipeptide to Dialysis Solutions in Peritoneal DialysisPeritoneal dialysis is a process of removing metabolic waste productsand excess water from the patient's body,replacing the function of the diseased kidneys.Currently, despite the clear benefits of PD, long-term treatment islimited due to an inherent lack ofbiocompatibility of current PD fluids. The combination of standard PDFsand alanyl-glutamine-dipeptide isdesigned as a cytoprotective PDF that allows a significantly longerduration of the treatment
EUCTR2012-004004-36-ATMed. Univ. Wien, UK für Kinder und Jugendheilkunde
招募中
3 期
Assessing the ability to detect tetrahydrocannabinol (THC) from cannabidiol (CBD) dominant medicinal cannabis products in patient samples of saliva, blood, and urineCancer
ACTRN12622000974707Mater Misericordiae Limited30